Anderson, Kenneth C.

Humanistic and Economic Impact of Subcutaneous Versus Intravenous Administration of Oncology Biologics

Anderson, K. C., Landgren, O., Arend, R. C., Chou, J., & Jacobs, I. A. (2019) · Future Oncology

Health Systems, Economic Evaluations, Quality of LifeEconomic and Financial Impacts of Cancer

Cited by 69

Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).

Attal, M., Palumbo, A., Holstein, S. A., Lauwers-Cances, V., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Anderson, K. C., Caillot, D., et al. (2016) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 63

Proteomic analysis of Waldenstrom macroglobulinemia

Hatjiharissi, E., Ngo, H., Leontovich, A. A., Leleu, X., Timm, M., Melhem, M., George, D., Lu, G., Ghobrial, J., Alsayed, Y., et al. (2007) · Cancer Research

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 61

Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD®immunomodulatory drug pomalidomide

Das, D. S., Ray, A., Song, Y., Richardson, P., Trikha, M., Chauhan, D., & Anderson, K. C. (2015) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 49

Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study

Kelly, K. R., Ailawadhi, S., Siegel, D. S., Heffner, L. T., Somlo, G., Jagannath, S., Zimmerman, T. M., Munshi, N. C., Madan, S., Chanan-Khan, A., et al. (2021) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 46

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Jagannath, S., Chanan-Khan, A., Heffner, L. T., Avigan, D., Zimmerman, T. M., Lonial, S., Lutz, R. J., Engling, A., Uherek, C., Osterroth, F., et al. (2011) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 44

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

Yu, T., Chaganty, B., Lin, L., Xing, L., Ramakrishnan, B., Wen, K., Hsieh, P. A., Wollacott, A., Viswanathan, K., Adari, H., et al. (2020) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 43

Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma

Nadeem, O., Magidson, S., Midha, S., O'Donnell, E. K., Hartley-Brown, M. A., Sperling, A. S., Redd, R. A., Marto, M., Davie, C., Ricciardi, C., et al. (2023) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 37

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry

Du, Z., Weinhold, N., Song, G. C., Rand, K. A., Van Den Berg, D. J., Hwang, A. E., Sheng, X., Hom, V., Ailawadhi, S., Nooka, A. K., et al. (2020) · Blood Advances

Multiple Myeloma Research and TreatmentsGenetic Associations and Epidemiology

Cited by 31

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status

Cea, M., Cagnetta, A., Acharya, C., Acharya, P., Tai, Y.-T., Yang, C., Lovera, D., Soncini, D., Miglino, M., Fraternali-Orcioni, G., et al. (2016) · Clinical Cancer Research

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 28

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma

Adamia, S., Bhatt, S., Wen, K., Chyra, Z., Fell, G. G., Tai, Y.-T., Pioso, M. S., Abiatari, I., Letai, A., Dorfman, D. M., et al. (2022) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 24

IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

Bazarbachi, A. H., Avet-Loiseau, H., Szalat, R., Samur, A. A., Hunter, Z., Shammas, M., Corre, J., Fulciniti, M., Anderson, K. C., Parmigiani, G., et al. (2021) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 21

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial

Nadeem, O., Aranha, M. P., Redd, R., Timonian, M., Magidson, S., Lightbody, E. D., Alberge, J.-B., Bertamini, L., Dutta, A. K., El-Khoury, H., et al. (2025) · Nature Communications

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 20

Development of hyperdiploidy starts at an early age and takes a decade to complete

Samur, M. K., Aktas Samur, A., Shah, P., Park, J. S., Fulciniti, M., Shammas, M., Corre, J., Anderson, K. C., Parmigiani, G., Avet-Loiseau, H., et al. (2025) · Blood

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 13

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

Richardson, P. G., Durie, B. G., Rosiñol, L., Mateos, M.-V., Dispenzieri, A., Moreau, P., Kumar, S., Raje, N., Munshi, N., Laubach, J. P., et al. (2023) · Haematologica

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 9